WraSer Pharmaceuticals, LLC (WraSer) announced that it has purchased the Trezix® Oral Capsule product from e5 Pharma, LLC. With the purchase, WraSer is granted full rights to market and distribute Trezix® in the United States.
Trezix® received final FDA approval in April 2007. The product combines Acetaminophen and Caffeine with the narcotic analgesic Dihydrocodeine, representing a safe and effective therapy for the treatment of mild to moderate pain. Physicians have few alternatives in prescribing a combination of Caffeine with a narcotic analgesic. Trezix® fills this important niche in the market for effective pain-management treatments.
“WraSer is pleased to add this unique therapy to our portfolio of pain management products,” said Cole Smelser, Executive Vice President of Sales for WraSer. “WraSer is looking to provide a broad spectrum of pain management options to the physicians and patients we serve. Trezix® is a great complement to our current and growing set of offerings in this market.”
Trezix® is available immediately to retail pharmacies and wholesale pharmacy distribution channels. Trezix® is available by prescription only. For full prescribing information, please contact WraSer Pharmaceuticals, LLC at the contact number listed below.
Telehealth mindfulness interventions significantly improve chronic pain outcomes for veterans